A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Inhibrx Biosciences, Inc
Trishula Therapeutics, Inc.
Actuate Therapeutics Inc.
University of California, San Francisco